Showing posts with label Think before you prescribe. Show all posts
Showing posts with label Think before you prescribe. Show all posts

Friday, September 14, 2018

Think before you prescribe - Consider dual therapy in patients with atrial fibrillation undergoing PCI and stenting



Dual antiplatelet therapy (DAPT), with aspirin and clopidogrel for 6-12 months, is usual after percutaneous coronary intervention (PCI) to prevent stent thrombosis and major adverse cardiac events (MACE) (J Thorac Cardiovasc Surg. 2016;152:1243-75). Because these patients are already on warfarin, an anti-Xa inhibitor (rivaroxaban or apixaban) or a direct thrombin inhibitor (dabigatran) as they have a separate indication for atrial fibrillation (AF), they are therefore subject to triple antiplatelet therapy increasing their risk of serious bleeding complications.

Data from the WOEST (What is the Optimal AntiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing) trial conducted in 15 centers in Belgium and the Netherlands show that compared with triple therapy, use of clopidogrel without aspirin was associated with a significant reduction in bleeding complications and no increase in the rate of thrombotic events. Bleeding episodes were seen in 19.4% patients receiving double therapy and in 44.4% receiving triple therapy (Lancet. Mar 30; 2013;381:1107-15).

A recently published systematic review and meta-analysis of four randomized clinical trials also concluded that dual antithrombotic may be a better option than triple antithrombotic therapy in many AF patients post-PCI. A reduction of 47% was noted in Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding with dual therapy in comparison to triple therapy (Eur Heart J. 2018 May 14;39:1726a-35a).

Trials like the RE-DUAL PCI (N Engl J Med. 2017 Oct 19;377(16):1513-1524) and PIONEER AF-PCI (N Engl J Med. 2016 Dec 22;375(25):2423-2434) further support the use of dual therapy in AF patients undergoing PCI with stent placement.

Another caution that must be exercised in these patients is with regard to the use of NSAIDs. A post hoc analysis of NSAIDs in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial has shown an association of NSAIDs with increased risk of major bleeding, stroke/SE, and hospitalization in AF patients (J Am Coll Cardiol. 2018 Jul 17;72(3):255-267).

Consider dual therapy in your patients with AF undergoing PCI with stent placement to prevent stent thrombosis and bleeding complications.

Thursday, September 13, 2018

Think before you prescribe Prescribe simpler drug regimens to improve treatment adherence






Compliance to prescribed treatment is a major factor influencing the desired treatment outcome and is largely dependent on the patient. Non-compliance with the drug treatment continues to be a common problem in practice. 

A systematic review of 76 studies examining the associations between dose regimens and medication compliance showed that the prescribed number of daily doses is inversely related to compliance. Adherence declined as the number of daily doses increased. Simpler, less frequent dosing regimens resulted in better compliance.  Compliance was significantly higher for once-daily vs 3-times-daily, once-daily vs 4-times-daily and twice-daily vs 4-times-daily regimens (Clin Ther. 2001;23:1296-1310).

Patients were again shown to be more compliant with once-daily compared with twice-daily or thrice-daily treatment regimens in another systematic review of 20 studies. Patients receiving once-daily dosing had 22% to 41% more adherent days compared with patients receiving thrice-daily dosing; patients receiving once-daily dosing had 2% to 44% more adherent days compared with patients receiving twice-daily dosing indicating that the once-daily dose regimen had the highest adherence rates in this study (Am J Manag Care. 2009;15:e22-e33).

Adherence with any medication regimen decreases with the number of doses prescribed. Therefore, if you prescribe a complex drug regimen with more number of medications, your patients are more likely to not respond well to treatment.  

So, to improve patient adherence to the treatment prescribed, keep it simple.


Dr KK Aggarwal
Padma Shri Awardee
Vice President CMAAO
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA

Tuesday, September 4, 2018

Think before you prescribe



Avoid concomitant use of fluoroquinolones with corticosteroids as much as possible: Monitor your patient for signs of tendon injury

The broad-spectrum fluoroquinolone antibiotics are used to treat common infections such as respiratory tract infections, urinary tract infections. However, their use is associated with serious adverse events regarding which the US FDA has issued safety communications.

In July 2008, the FDA mandated the first black box warning for fluoroquinolone antibiotics for increased risk of tendinitis and tendon rupture. Since then, other black box warnings have been issued: August 2013 (peripheral neuropathy), May 2016 (restricting use for certain uncomplicated infections), July 2016 (disabling side effects) and the most recent being in July 2018 (hypoglycemia and mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium).

A study conducted in 2012 showed the strong association of fluoroquinolones with increased risk of Achilles tendonitis and tendon rupture, especially in those who also used oral glucocorticoids at the same time (Am J Med. 2012;125(12):1228.e23-1228.e28). In a study from Italy, concomitant use of corticosteroids and fluoroquinolones was associated with a threefold increased risk for tendon rupture and a 43-fold greater risk of rupture of Achilles tendon (Drug Saf. 2006;29(10):889-96).

Patient safety is a very important aspect of delivery of health care. Hence, the use of fluoroquinolones with corticosteroid must be avoided as much as possible, especially in the elderly patients with renal insufficiency or other risk factors, due to increased risk of potentially disabling fluoroquinolone-associated tendinitis (Pharmacy Times. April 11, 2016). Patients receiving this combination should be carefully monitored for any sign of tendon injury. Discontinue the drugs as soon as signs are detected and minimize activity until the symptoms resolve.


Dr KK Aggarwal
Padma Shri Awardee
Vice President CMAAO
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA


Wednesday, August 29, 2018

Think before you prescribe - Do not give nitrofurantoin in suspected pyelonephritis


Think before you prescribe

Do not give nitrofurantoin in suspected pyelonephritis

Nitrofurantoin is an effective and therefore often the first-line choice for cystitis. A 2010 update of the guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis (Clin Infect Dis. 2011;52:e103-e120) recommends against the use of nitrofurantoin when the diagnosis of cystitis is uncertain vis-à-vis pyelonephritis, because it does not achieve adequate renal tissue levels. According to the guideline, “such uncertainly may exist in the setting of cystitis symptoms accompanied by subjective fever that is not verified at the time of examination, a prolonged duration of cystitis symptoms (typically greater than 5-7 days), or vague flank pain or tenderness which is not otherwise explained”.

In such cases, a urine culture and susceptibility test should always be done and choice of antibiotic should be based on the culture and antibiotic sensitivity testing. Local community resistance prevalence, availability, cost, patient allergy and compliance history are other factors that may influence the choice of antibiotic in these patients.

Dr KK Aggarwal
Padma Shri Awardee
Vice President CMAAO
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA

Saturday, August 25, 2018

Think before you prescribe Combination of ACEI/ARBs + diuretic + NSAID may be nephrotoxic




Triple therapy with NSAIDs, diuretics and an ACEI/ARB is associated with increased risk of acute kidney injury.  In the retrospective cohort study of almost 500 000 patients published in BMJ. 2013 Jan 8;346:e8525, the overall risk increased by 31% with the simultaneous use of these three drugs. The use of a double therapy combination containing either a diuretic or ACEI or ARB with NSAIDs was not associated with an increased rate of acute kidney injury.

Since the observed risk was greatest at the start of treatment “first 30 days of use”, caution is warranted, especially during the initial few months of therapy. Monitor BP and serum creatinine when more than two anti-hypertensive drugs are used in combination with NSAIDs.


Dr KK Aggarwal
Padma Shri Awardee
Vice President CMAAO
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA


Thursday, August 23, 2018

Think before you prescribe




Consider a more convenient option when prescribing antiviral drug for herpes zoster

Herpes zoster or shingles is a viral infection characterized by pain followed by a vesicular rash. It is caused by reactivation of the varicella zoster virus (VZV). The aim of treatment is to hasten healing, reduce the severity and duration of pain and also to reduce the chances of complications such as post-herpetic neuralgia.

Timely administration of antiviral drugs - acyclovir, valacyclovir and famciclovir – decreases viral shedding and reduces the acute pain in patients with uncomplicated infection. These clinical benefits have been demonstrated in various clinical trials.

Acyclovir has to be administered five times daily, which may hinder patient compliance to prescribed treatment. This is especially of concern in the elderly, in whom herpes zoster is most prevalent.

The prodrug of acyclovir, valacyclovir, is administered thrice daily as treatment for herpes zoster and the serum levels achieved are 3 to 5 times higher than those obtained with oral acyclovir.

Famciclovir is a prodrug of penciclovir and is also administered thrice daily as treatment for herpes zoster.

Therefore, when compliance is a concern or convenience of dosing is required, valacyclovir and famciclovir are useful and convenient alternatives to acyclovir as treatment for herpes zoster. 

Dr KK Aggarwal
Padma Shri Awardee
Vice President CMAAO
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA